Red X iconGreen tick iconYellow tick icon
Skip to main content Skip to side navigation
  • Gardiner SJ, Kristensen JH, Begg EJ, Hackett LP, Wilson DA, Ilett KF, Kohan R, Rampono J. Transfer of olanzapine into breast milk, calculation of infant drug dose, and effect on breast-fed infants. Am J Psychiatry 2003; 160(8), 1428-31 [Abstract]
  • Gearry RB, Barclay ML, Burt MJ, Collett JA, Chapman BA, Roberts RL, Kennedy MA. Thiopurine S-methyltransferase (TPMT) genotype does not predict adverse drug reactions to thiopurine drugs in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2003; 18(4), 395-400 [Abstract]
  • Aronson JK, Lennard MS, Ritter JM, Baber NS, Begg EJ. BJCP Editors' report for 2002. Br J Clin Pharmacol 2003; 55(4), 329-30 [Abstract]
  • Gardiner SJ, Kirkpatrick CMJ, Begg EJ, Zhang M, Moore MP, Saville DJ. Transfer of metformin into human milk. Clin Pharmacol Ther 2003 Jan; 73(1), 71-7 [Abstract]
  • Gardiner SJ. Systemic oral antifungals: clinically relevant drug interactions. New Ethicals 2003; 6(2), 43-8 [No abstract]
  • Begg EJ, Sidwell AI, Gardiner SJ, Nicholls MG, Scott RS. The sorry saga of the statins in New Zealand - pharmacopolitics versus patient care. NZ Med J 2003; 116(1170), U360 (letter) [ref]
  • Sidwell A, Barclay ML, Begg EJ, Moore G. Digoxin therapeutic drug monitoring: and audit and review. NZ Med J 2003; 116(1187), U708 [Abstract]
  • Barclay ML, Begg EJ. The practice of digoxin therapeutic drug monitoring. NZ Med J 2003; 116(1187), U704 (Editorial) [ref]
  • Gearry R, Barclay M, Gardiner S, Zhang M. 6-Thioguanine nucleotides and thiopurine methyltransferase activity: important factors determining response to treatment and incidence of adverse effects from azathioprine and 6-MP. NZ Med J 2003; 116(1178), U351 (letter) [ref]
  • Barclay ML, Sawyers SM, Begg EJ, Zhang M, Roberts RL, Kennedy MA, Elliott JM. Correlation of CYP2D6 genotype with perhexiline phenotypic metabolizer status. Pharmacogenetics 2003 Oct;13(10), 627-32 [Abstract]
  • Kirkpatrick CM, Duffull SB, Frampton C, Begg EJ. The use of a change in gentamicin clearance as an early predictor of gentamicin-induced nephrotoxicity. Ther Drug Monit 2003; 25(5), 623-30 [Abstract]
  • Begg E. Clinical pharmacology essentials: the principles behind the prescribing process (Book). Lippincott Williams & Wilkins 2003 [Ref]
  • Howard G, Barclay M, Florkowski C, Moore G, Roche A. Lack of clinically significant interference by spironolactone with the AxSYM digoxin II assay. Ther Drug Monit 2003; 25(1), 112-3 [Abstract]
  • MacLeod AD, Vella-Brincat J, Frampton C. Swallowing capsules. Palliat Med 2003; 17(6), 559 [Abstract]
Back to top